Literature DB >> 7513744

Differential host-dependent expression of alpha-galactosyl epitopes on viral glycoproteins: a study of eastern equine encephalitis virus as a model.

P M Repik1, J M Strizki, U Galili.   

Abstract

The carbohydrate epitope Gal alpha 1-3Gal beta 1-4GlcNAc-R (alpha-galactosyl) is abundantly expressed on cells of non-primate mammals, prosimians and New World monkeys, where it is synthesized by the enzyme alpha 1,3-galactosyltransferase (alpha 1,3GT). Old World monkeys, apes and humans lack alpha 1,3GT and hence do not synthesize alpha-galactosyl epitopes. Instead, these species produce a natural antibody, anti-Gal, which interacts specifically with alpha-galactosyl epitopes and which constitutes up to 1% of circulating immunoglobulins in humans. We have used eastern equine encephalitis (EEE) virus as a model to examine the differential expression of alpha-galactosyl epitopes on the glycoproteins of virus propagated in cells that either produce or lack alpha 1,3GT. As predicted, virus propagated in Vero cells (derived from the African green monkey, an Old World monkey) did not express alpha-galactosyl epitopes. In contrast, virus propagated in mouse 3T3 cells (EEE3T3) expressed approximately 80 alpha-galactosyl epitopes per virion on both the E1 and the E2 envelope glycoproteins. Thus, expression of the alpha-galactosyl epitope on virions paralleled that on host cells. The binding of anti-Gal antibody to these epitopes on EEE3T3 virions partially neutralized virus infectivity, raising the possibility that anti-Gal production in hosts may influence the initial infectious stage of viruses expressing alpha-galactosyl epitopes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7513744     DOI: 10.1099/0022-1317-75-5-1177

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  12 in total

Review 1.  Significance of the evolutionary α1,3-galactosyltransferase (GGTA1) gene inactivation in preventing extinction of apes and old world monkeys.

Authors:  Uri Galili
Journal:  J Mol Evol       Date:  2014-10-15       Impact factor: 2.395

2.  Genetic and structural basis of the human anti-α-galactosyl antibody response.

Authors:  David B Langley; Peter Schofield; Damien Nevoltris; Jennifer Jackson; Katherine J L Jackson; Tim J Peters; Melanie Burk; Jacqueline M Matthews; Antony Basten; Christopher C Goodnow; Sheryl van Nunen; Joanne H Reed; Daniel Christ
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-08       Impact factor: 12.779

Review 3.  The Galalpha1,3Galbeta1,4GlcNAc-R (alpha-Gal) epitope: a carbohydrate of unique evolution and clinical relevance.

Authors:  Bruce A Macher; Uri Galili
Journal:  Biochim Biophys Acta       Date:  2007-11-22

Review 4.  Anti-Gal: an abundant human natural antibody of multiple pathogeneses and clinical benefits.

Authors:  Uri Galili
Journal:  Immunology       Date:  2013-09       Impact factor: 7.397

5.  DC-SIGN and L-SIGN can act as attachment receptors for alphaviruses and distinguish between mosquito cell- and mammalian cell-derived viruses.

Authors:  William B Klimstra; Elizabeth M Nangle; M Shane Smith; Andrew D Yurochko; Kate D Ryman
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

Review 6.  Acceleration of wound healing by α-gal nanoparticles interacting with the natural anti-Gal antibody.

Authors:  Uri Galili
Journal:  J Immunol Res       Date:  2015-04-01       Impact factor: 4.818

Review 7.  Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present α-gal epitopes.

Authors:  Uri Galili
Journal:  Vaccine       Date:  2020-08-19       Impact factor: 3.641

8.  A novel mechanism of retrovirus inactivation in human serum mediated by anti-alpha-galactosyl natural antibody.

Authors:  R P Rother; W L Fodor; J P Springhorn; C W Birks; E Setter; M S Sandrin; S P Squinto; S A Rollins
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

Review 9.  SARS-CoV-2 replicating in nonprimate mammalian cells probably have critical advantages for COVID-19 vaccines due to anti-Gal antibodies: A minireview and proposals.

Authors:  Ji-Ming Chen
Journal:  J Med Virol       Date:  2020-08-02       Impact factor: 20.693

Review 10.  Live unattenuated vaccines for controlling viral diseases, including COVID-19.

Authors:  Ji-Ming Chen
Journal:  J Med Virol       Date:  2020-09-29       Impact factor: 20.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.